Thus, Treg cells play a key role in tumor immune tolerance, and the HSP70 inhibitor TPL significantly reduced the proportion of Treg cells in the spleen and axillary lymph nodes of tumor-bearing mice and decreased Foxp3 levels and secretion of IL-10 and TGF-β in peripheral blood (Liu et al., 2013), these data reflect the possibility that TPL may counteract tumor immune responses and inhibit tumor growth by suppressing Treg cells and immunosuppressive factors. The gene discussed is FOXP3; the disease is neoplasm.